Re: Farmas USA
Me acaba de llegar, nuevas coverturas .
Healthcare ratings roundup - new coverage
Jun 10 2016, 07:19 ET | By: Douglas W. House, SA News Editor
Boston Scientific (NYSE: BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
Zimmer Biomet Holdings (NYSE: ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
Edwards Lifesciences (NYSE: EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
Oncobiologics (Pending: ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
Walgreens Boots Alliance (NASDAQ: WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ: JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ: HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ: ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE: MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ: MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ: CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ: IPXL) - $33 (2% downside risk) price target.
Biocept (NASDAQ: BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
Seres Therapeutics (NASDAQ: MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
Omeros (NASDAQ: OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
Glaukos (NYSE: GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
Shire plc (NASDAQ: SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.